We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DuoCort Pharma and Recipharm Start Innovative Collaboration

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DuoCort Pharma and Recipharm Start Innovative Collaboration"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
DuoCort Pharma announces it has concluded an agreement with Recipharm under which Recipharm is set to scale-up the manufacturing of DuoCort’s tablets to commercial scale as DuoCort Pharma prepares for market entry with its orphan drug for the treatment of Addison’s disease.

The scale-up agreement represents an innovative risk sharing collaboration in which Recipharm, one of Europe’s leading pharmaceutical Contract Development and Manufacturing Organisations, will co-invest in the scale-up along with DuoCort Pharma.

The Swedish speciality pharma company, DuoCort Pharma, took a step closer to the market earlier this year when it filed for marketing authorization in the EU for its new treatment for the rare and life threatening disease adrenal insufficiency, often referred to as Addison’s disease.

Although cortisol replacement therapy for adrenal insufficiency has been around for a long time, several studies have recorded premature death, impaired quality of life, increased risk of cardiovascular diseases and decreased bone mineral density in these patients. Existing replacement therapies, unable to mimic cortisol’s normal diurnal release profiles, are viewed as the likely cause of these outcomes. The new treatment from DuoCort Pharma has a physiological release profile which mimics the body’s natural release of cortisol, thereby improving treatment outcomes.

“We are very pleased to be working with an organization of Recipharm’s calibre to scale-up our tablet manufacturing process. It is a real endorsement of the quality and commercial potential of our drug development that Recipharm has chosen to co-invest in this with us,” commented Maria Forss, CEO of DuoCort Pharma.